Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633994 | 0.89 | PPARG (0.44) | PTPN1PPARGPPARAEDNRAKMT2A | |
| SCHEMBL4603622 | 0.87 | PTPN1 (0.52) | PTPN1PPARGPPARAEDNRAPTGS2 | |
| SCHEMBL4606731 | 0.84 | PTPN1 (0.52) | PTPN1PPARGPPARAEDNRAPTGS2 | |
| SCHEMBL4605156 | 0.75 | KMT2A (0.47) | PTPN1PPARGPPARAEDNRAKMT2A | |
| SCHEMBL4605133 | 0.75 | ALDH1A1 (0.51) | PTPN1EDNRAPTGS2KMT2AMAPT | |
| SCHEMBL4634461 | 0.74 | ABCC1 (0.43) | PTPN1PPARGPPARANPC1KMT2A | |
| SCHEMBL4605351 | 0.74 | ALDH1A1 (0.48) | PTPN1PPARGPPARAKMT2AALDH1A1 | |
| SCHEMBL4606177 | 0.73 | PPARG (0.44) | PTPN1PPARGPPARAEDNRAKMT2A | |
| SCHEMBL4605028 | 0.72 | KMT2A (0.49) | PTPN1PPARGPPARAEDNRAKMT2A | |
| SCHEMBL4635079 | 0.72 | ABCC1 (0.44) | PTPN1PPARGPPARANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685121-B1 | ANTIDIABETIC COMPOUNDS COMPRISING BENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-7375130-B2 | Antidiabetic compounds comprising benzofuran and benzothiophene derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20070078178-A1 | Antidiabetic compounds comprising benzofuran and benzothiophene derivatives | MERCK PATENT GMBH (DE) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078178-A1 | Antidiabetic compounds comprising benzofuran and benzothiophene derivatives | GPR119, INSR, GLP1R | PTPN1 1650/4885PPARG 44/4885PPARA 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.